David Friedman

Notable Levi Strauss Insider Trades $830K In Company Stock

6 Months In, Trump Has Filled Only 27 Out Of More The 200 Envoy Posts, Mostly With Cronies

Exclusive: Wealth-X President On Expanding Ultra High-Net-Wealthy Population And Spending Habits

6 Months In, Trump Has Filled Only 27 Out Of More The 200 Envoy Posts, Mostly With Cronies

Exclusive: Wealth-X President On Expanding Ultra High-Net-Wealthy Population And Spending Habits

UPDATE: Morgan Stanley Reiterates On Theravance As Slow Trends Weigh On Value

UPDATE: Morgan Stanley Reiterates On Idenix Pharmaceuticals Due To Likely Merck Acquisition

UPDATE: Morgan Stanley Reiterates On Theravance As Slow Trends Weigh On Value

UPDATE: Morgan Stanley Reiterates On Idenix Pharmaceuticals Due To Likely Merck Acquisition

UPDATE: Morgan Stanley Reiterates On Incyte On ASCO Abstracts

UPDATE: Morgan Stanley Reiterates On Theravance Following Anoro Launch

David Friedman Recent News

GW Pharma Soars 35% on Initiation from Morgan Stanley, Bullish Comments by Jim Cramer

UPDATE: Morgan Stanley Reiterates on Synageva BioPharma as Brain-Blood Barrier Study is Good Next Step

UPDATE: Morgan Stanley Reiterates on Chimerix as New AdV Trial Highlights Broad Brincidofovir Potential

UPDATE: Morgan Stanley Downgrades Auxilium Pharmaceuticals as Growth May Not Match High Valuation

UPDATE: Morgan Stanley Initiates Coverage on Ultragenyx Pharmaceutical on Growing Orphan Drug Pipeline

Morgan Stanley Expects Theravance to Continue to Underperform Following 4Q Earnings

UPDATE: Morgan Stanley Downgrades Alnylam Pharmaceuticals, Sees Robust Drug Prospects

UPDATE: Morgan Stanley Downgrades Neurocrine Biosciences on Recent Stock Appreciation

UPDATE: Morgan Stanley Initiates Coverage on Relypsa on Large Opportunity in K+ Control

Morgan Stanley Reiterates Equal-Weight Rating on InterMune Following 2Q Sales Results

UPDATE: Morgan Stanley Initiates Portola Pharmaceuticals at Overweight on Drugs Potentially Fulfilling Serious Medical Need

UPDATE: Morgan Stanley Initiates Alnylam Pharmaceuticals at Overweight on Market Leader Position

UPDATE: Morgan Stanley Initiates Alnylam Pharmaceuticals at Overweight on Positively Viewed Amyloidosis Program

UPDATE: Morgan Stanley Downgrades XenoPort on Recent Failures

UPDATE: Morgan Stanley Downgrades Lexicon Pharmaceuticals on Challenged Valuation